Undifferentiated connective tissue disease medical therapy
Undifferentiated connective tissue disease Microchapters |
Differentiating Undifferentiated connective tissue disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Undifferentiated connective tissue disease medical therapy On the Web |
American Roentgen Ray Society Images of Undifferentiated connective tissue disease medical therapy |
FDA on Undifferentiated connective tissue disease medical therapy |
CDC on Undifferentiated connective tissue disease medical therapy |
Undifferentiated connective tissue disease medical therapy in the news |
Blogs on Undifferentiated connective tissue disease medical therapy |
Directions to Hospitals Treating Undifferentiated connective tissue disease |
Risk calculators and risk factors for Undifferentiated connective tissue disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis.
Medical Therapy
- Pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient:
Arthritis and dermatitis
- Oral regimen
- Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)[1]
- Dose is gradually increased to 13.6 mg after 6 months
- Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)[1]
PO q12h for 14 (14–21) days (maximum, 500 mg per dose)